TP53 Gene Promoter Methylation Impacts Chronic Lymphocytic Leukemia
|
By LabMedica International staff writers Posted on 11 Dec 2019 |
|
Image: Peripheral blood smear showing chronic lymphocytic leukemia (CLL). A large lymphocyte (arrow) has a notched nucleus and demonstrates the variable appearance of some of the lymphocytes in CLL (Photo courtesy of Peter Maslak)
Chronic lymphocytic leukemia (CLL) is a clonal disorder that results in the accumulation of morphologically mature-looking and immunologically incompetent lymphoid cells in the bone marrow, peripheral blood, and lymphatic tissues.
CLL is a heterogeneous disease as some patients may progress rapidly, even though they may fail to respond to therapy, and others may remain stable for years without any intervention, and this mirrors the genetic configuration and the epigenetic modification of different genes that lead to disease development, stability, progression, and response to different chemotherapeutic agents.
Scientists at the University of Duhok (Duhok, Iraq) carried out a case-control study including 54 newly diagnosed patients presenting with CLL as well as 30 normal individuals as controls from January 1, 2017 to July 30, 2018. Blood was collected from all enrolled individuals for hematological investigations as well as for molecular categorization of TP53 methylation status. Methylation-specific polymerase chain reaction (MS-PCR) technique was used to define the methylation status of the TP53 gene promoter that encompasses DNA extraction, bisulfite conversion, conventional PCR amplification, running on agarose gel and documentation. Amplification was performed using a 2729 PCR thermal cycler (Applied Biosystems, Foster City, CA, USA).
The scientists reported that all controls and 42 of 54 patients show unmethylated TP53 gene promoter; on the other hand, the methylated promoter was detected among 12 CLL patients. TP53 gene promoter methylation significantly linked to reduced platelet count and advanced stage at presentation. No significant differences were seen among both methylated and unmethylated TP53 promoters in relation to the age of the affected individuals, total white blood cell counts and hemoglobin level of the affected individuals.
The authors concluded that their study revealed that TP53 methylation contributes significantly to CLL development and progression. Further workups are recommended to study their relation with other genetic changes as malignancies are multifactorial and heterogeneous that arises from the interaction of different genetic changes. The study was published on November 25, 2019 in the Journal of Blood Medicine.
Related Links:
University of Duhok
Applied Biosystems
CLL is a heterogeneous disease as some patients may progress rapidly, even though they may fail to respond to therapy, and others may remain stable for years without any intervention, and this mirrors the genetic configuration and the epigenetic modification of different genes that lead to disease development, stability, progression, and response to different chemotherapeutic agents.
Scientists at the University of Duhok (Duhok, Iraq) carried out a case-control study including 54 newly diagnosed patients presenting with CLL as well as 30 normal individuals as controls from January 1, 2017 to July 30, 2018. Blood was collected from all enrolled individuals for hematological investigations as well as for molecular categorization of TP53 methylation status. Methylation-specific polymerase chain reaction (MS-PCR) technique was used to define the methylation status of the TP53 gene promoter that encompasses DNA extraction, bisulfite conversion, conventional PCR amplification, running on agarose gel and documentation. Amplification was performed using a 2729 PCR thermal cycler (Applied Biosystems, Foster City, CA, USA).
The scientists reported that all controls and 42 of 54 patients show unmethylated TP53 gene promoter; on the other hand, the methylated promoter was detected among 12 CLL patients. TP53 gene promoter methylation significantly linked to reduced platelet count and advanced stage at presentation. No significant differences were seen among both methylated and unmethylated TP53 promoters in relation to the age of the affected individuals, total white blood cell counts and hemoglobin level of the affected individuals.
The authors concluded that their study revealed that TP53 methylation contributes significantly to CLL development and progression. Further workups are recommended to study their relation with other genetic changes as malignancies are multifactorial and heterogeneous that arises from the interaction of different genetic changes. The study was published on November 25, 2019 in the Journal of Blood Medicine.
Related Links:
University of Duhok
Applied Biosystems
Gold Member
Hematology Analyzer
Medonic M32B
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Capillary Blood Collection Tube
IMPROMINI M3
Latest Molecular Diagnostics News
- Urine Test Detects Early Stage Pancreatic Cancer
- Genomic Test Could Reduce Lymph Node Biopsy Surgery in Melanoma Patients
- Urine Test Could Replace Painful Kidney Biopsies for Lupus Patients
- Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer
- Mitochondrial DNA Mutations from Kidney Stressors Could Predict Future Organ Decline
- Blood Test Could Predict Bariatric Surgery Outcomes in Teenagers
- ctDNA Blood Test to Help Personalize Postsurgical Colon Cancer Treatment
- AI Powered Blood Test Predicts Suicide Risk in Bipolar Patients
- DNA Sensor Enables Molecular Detection from Single Blood Drop
- DNA-Powered Test Accurately Detects E. Coli Lookalike Bacteria
- World’s Fastest DNA Sequencing Technique to Revolutionize NICU Genomic Care
- Blood Test Uses Cell-Free DNA to Detect ALS Faster and More Accurately
- Multi-Cancer Early Detection Blood Test Increases Cancer Detection
- Portable Label-Free Device Tracks Alzheimer's Disease in Real Time
- Liquid Biopsy Test Enables Early Detection of ICI-Related Myocarditis
- Rapid POC Diagnostic Test Detects Asymptomatic Malaria Cases
Channels
Clinical Chemistry
view channel
VOCs Show Promise for Early Multi-Cancer Detection
Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read more
Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
Kidney disease is typically diagnosed through blood or urine tests, often when patients present with symptoms such as blood in urine, shortness of breath, or weight loss. While these tests are common,... Read more
Molecular Diagnostics
view channel
Urine Test Detects Early Stage Pancreatic Cancer
Pancreatic cancer remains among the hardest cancers to detect early. In the UK, around 10,000 people are diagnosed each year, but only 5% survive beyond five years. Late diagnosis is a major factor—more... Read more
Genomic Test Could Reduce Lymph Node Biopsy Surgery in Melanoma Patients
Accurately determining whether melanoma has spread to the lymph nodes is crucial for guiding treatment decisions, yet the standard procedure—sentinel lymph node biopsy—remains invasive, costly, and unnecessary... Read more
Immunology
view channel
Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. Many patients undergo costly and taxing treatment... Read more
Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
Modern cancer immunotherapies rely on the ability of CD8⁺ T cells to rapidly multiply within tumors, generating the immune force needed to eliminate cancer cells. However, the biological triggers behind... Read more
Microbiology
view channel
High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
Candida bloodstream infections are a growing global health threat, causing an estimated 6 million cases and 3.8 million deaths annually. Hospitals are particularly vulnerable, as weakened patients after... Read more
Pathology
view channel
New Molecular Analysis Tool to Improve Disease Diagnosis
Accurately distinguishing between similar biomolecules such as proteins is vital for biomedical research and diagnostics, yet existing analytical tools often fail to detect subtle structural or compositional... Read more
Tears Offer Noninvasive Alternative for Diagnosing Neurodegenerative Diseases
Diagnosing and monitoring eye and neurodegenerative diseases often requires invasive procedures to access ocular fluids. Ocular fluids like aqueous humor and vitreous humor contain valuable molecular information... Read more
Technology
view channel
Cell-Sorting Device Uses Electromagnetic Levitation to Precisely Direct Cell Movement
Sorting different cell types—such as cancerous versus healthy or live versus dead cells—is a critical task in biology and medicine. However, conventional methods often require labeling, chemical exposure,... Read more
Embedded GPU Platform Enables Rapid Blood Profiling for POC Diagnostics
Blood tests remain a cornerstone of medical diagnostics, but traditional imaging and analysis methods can be slow, costly, and reliant on dyes or contrast agents. Now, scientists have developed a real-time,... Read more
Industry
view channel
Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
QIAGEN (Venlo, Netherlands) has entered into a definitive agreement to fully acquire Parse Biosciences (Seattle, WA, USA), a provider of scalable, instrument-free solutions for single-cell research.... Read more
Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
Puritan Medical Products (Guilford, ME, USA), the world’s most trusted manufacturer of swabs and specimen collection devices, is set to exhibit at AMP2025 in Boston, Massachusetts, from November 11–15.... Read more
Advanced Instruments Merged Under Nova Biomedical Name
Advanced Instruments (Norwood, MA, USA) and Nova Biomedical (Waltham, MA, USA) are now officially doing business under a single, unified brand. This transformation is expected to deliver greater value... Read more
